LinkedIn Profile

Access Xellia Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:xellia 1181570 Feb 16th, 2020 12:00AM Xellia Pharmaceuticals 28K 1209 Open Pharmaceuticals Feb 16th, 2020 06:06PM Feb 16th, 2020 06:06PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 15th, 2020 12:00AM Xellia Pharmaceuticals 27K 1210 Open Pharmaceuticals Feb 15th, 2020 12:49AM Feb 15th, 2020 12:49AM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 14th, 2020 12:00AM Xellia Pharmaceuticals 27K 1210 Open Pharmaceuticals Feb 14th, 2020 02:37PM Feb 14th, 2020 02:37PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 13th, 2020 12:00AM Xellia Pharmaceuticals 27K 1210 Open Pharmaceuticals Feb 13th, 2020 05:49PM Feb 13th, 2020 05:49PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 12th, 2020 12:00AM Xellia Pharmaceuticals 27K 1208 Open Pharmaceuticals Feb 12th, 2020 02:28PM Feb 12th, 2020 02:28PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 11th, 2020 12:00AM Xellia Pharmaceuticals 27K 1208 Open Pharmaceuticals Feb 11th, 2020 10:58AM Feb 11th, 2020 10:58AM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 10th, 2020 12:00AM Xellia Pharmaceuticals 27K 1208 Open Pharmaceuticals Feb 10th, 2020 01:21PM Feb 10th, 2020 01:21PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 8th, 2020 12:00AM Xellia Pharmaceuticals 27K 1208 Open Pharmaceuticals Feb 8th, 2020 05:33PM Feb 8th, 2020 05:33PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 7th, 2020 12:00AM Xellia Pharmaceuticals 27K 1210 Open Pharmaceuticals Feb 7th, 2020 12:50AM Feb 7th, 2020 12:50AM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Feb 6th, 2020 12:00AM Xellia Pharmaceuticals 27K 1210 Open Pharmaceuticals Feb 6th, 2020 12:53AM Feb 6th, 2020 12:53AM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.